Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q2 2020 Earnings Conference Call August 6, 2020 5:00 PM ET Company Participants Dan Dischner – Vice President of Human Resources and Corporate Communications Bill Peters – Chief Financial Officer Tony Marrs – Senior Vice President of Regulatory Affairs and Clinical Operations Conference Call Participants Tim Chiang – Northland Capital Markets David Amsellem – Piper Sandler Rafay Sardar – BMO Capital Markets David Steinberg – Jefferies Tian Sun – Needham & Compan ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2020 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 | --- | --- | |----------------------------------------------------------------------------------------------------- ...

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q1 2020 Earnings Conference Call May 7, 2020 5:00 PM ET Company Participants Dan Dischner - VP of Corporate Communications Tony Marrs - VP of Clinical Research William Peters - CFO, Treasurer & Senior VP of Finance Conference Call Participants Tim Chiang - Northland Securities Gary Nachman - BMO Capital Markets Lucas Lee - Raymond James David Steinberg - Jefferies Operator [Abrupt Start] All statements on this conference call that are not historical are forward- ...

Table of Contents | --- | |-------------------------------------------------------------------------------------| | | | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | | FORM 10-Q | ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2020 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 | --- | ...

| --- | --- | |-------|---------------------------------------------------------------------------------| | | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | | | FORM 10-K | ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to _____ Commission File Number 001-36509 AMPHASTAR ...

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q4 2019 Results Conference Call March 12, 2020 5:00 PM ET Company Participants Jason Shandell - President Bill Peters - Chief Financial Officer Conference Call Participants Rafay Sardar - BMO Capital Markets Lucas Lee - Raymond James David Steinberg - Jefferies David Amsellem - Piper Sandler Tian Sun - Needham & Company Operator Ladies and gentlemen, thank for standing by, and welcome to the Amphastar fourth quarter earnings call. [Operator Instructions] I'll no ...